Medical

Search documents
Cerus(CERS) - 2024 Q3 - Earnings Call Presentation
2025-07-09 13:11
Financial Performance & Guidance - Cerus is raising its full-year 2024 product revenue guidance to $177 - $179 million, anticipating a 12-14% increase compared to full-year 2023 product revenue[13] - The bottom end of the 2024 IFC guidance range has been raised to $9 - $10 million, from the prior $8 - $10 million[13] - In Q3 2024, Non-GAAP Adjusted EBITDA reached $4.4 million[32] Product & Market - The global addressable market for INTERCEPT products is estimated at $1.3 billion, with potential growth to over $1.5 billion in 5-7 years[22] - The U S addressable market is $150 million, with potential growth to over $200 million in 5-7 years[22] - Cerus' preliminary 2023 product revenue was $156 million[22] Strategic Initiatives - Cerus has a new BARDA contract for INTERCEPT RBCs[11] - The company submitted a CE Mark for its LED Illuminator[11] - Cerus is focused on adjusted EBITDA and operating cash flow goals[25]
Cerus(CERS) - 2024 Q4 - Earnings Call Presentation
2025-07-09 13:11
Financial Performance & Outlook - Cerus achieved positive non-GAAP adjusted EBITDA for Q4 and full year 2024 [9] - The company anticipates product revenue growth of 8% to 11% year-over-year in 2025 [9] - Cerus is committed to sustaining positive adjusted EBITDA for fiscal year 2025 [9] - GAAP net loss attributable to Cerus improved by over 40% in 2024 compared to 2023 [9] - In 2024, Cerus achieved 15% topline growth due to strong team performance and blood center partnerships [10] Market & Product Expansion - Cerus is focused on the continued global expansion of its platelet franchise [9] - The company expects increasing uptake of INTERCEPT Fibrinogen Complex (IFC) in the US [9] - The global addressable market for INTERCEPT products is currently $1.3 billion and is expected to grow to over $1.5 billion in the next 5-7 years [16] - The U S addressable market is $150 million and is expected to grow to over $200 million in the next 5-7 years [16] Technology & Impact - Cumulative kit sales for over 16 million INTERCEPT treated doses of platelets & plasma [5]
Strength Seen in Progyny (PGNY): Can Its 13.2% Jump Turn into More Strength?
ZACKS· 2025-07-09 12:36
Company Overview - Progyny (PGNY) shares increased by 13.2% to $24.27 in the last trading session, with a higher-than-average trading volume, contrasting with a 2.4% loss over the past four weeks [1] - The company is a provider of fertility and family building benefits [2] Financial Performance Expectations - Progyny anticipates its Q2 2025 financial results (revenues, adjusted net income, and adjusted EBITDA) to exceed the guidance provided during the Q1 earnings call [2] - The expected quarterly earnings per share (EPS) is $0.42, reflecting a year-over-year decline of 2.3%, while revenues are projected to be $314.93 million, an increase of 3.6% from the previous year [3] Earnings Estimate Trends - The consensus EPS estimate for Progyny has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook [4] Industry Context - Progyny is part of the Zacks Medical Services industry, which includes other companies like Enhabit (EHAB), which experienced a 0.3% decline in the last trading session and has returned -32.1% over the past month [4] - Enhabit has a consensus EPS estimate of $0.1 for its upcoming report, representing a 42.9% increase from the previous year, and also holds a Zacks Rank of 3 (Hold) [5]
Vireo Growth Inc. Announces Retirement of November 2024 Convertible Note
Globenewswire· 2025-07-09 12:30
-- Company concurrently refinances convertible note on amended terms in conjunction with larger refinancing -- MINNEAPOLIS, July 09, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (“Vireo” or the “Company”) (CSE: VREO; OTCQX: VREOF) today announced the retirement of its previously outstanding US$10 million principal amount convertible note issued on November 1, 2024. Concurrently with the retirement of the November 1, 2024 convertible note, on July 7, 2025, the Company issued a new US$10 million principal amoun ...
Helius Medical Technologies, Inc. Compliant with Nasdaq’s Continued Listing Requirements
Globenewswire· 2025-07-09 12:30
NEWTOWN, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that on July 7, 2025, Helius received formal notice from the Nasdaq Hearings Panel of the Nasdaq Stock Market LLC (the “Panel”) indicating that Helius has evidenced compliance with the equity requirement in Listing Rule 5550(b)(1) (the “Equity Rule”) f ...
Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2025 Financial Results
Prnewswire· 2025-07-09 11:30
Core Viewpoint - Zimmer Biomet Holdings, Inc. will host its second quarter earnings conference call on August 7, 2025, at 8:30 a.m. ET, with a news release detailing the quarterly results available at 6:30 a.m. ET on the same day [1]. Company Overview - Zimmer Biomet is a global leader in medical technology, offering a comprehensive portfolio aimed at maximizing mobility and improving health [3]. - The company has over 90 years of trusted leadership and expertise, focusing on delivering high-quality solutions to patients and providers [4]. - Zimmer Biomet operates in more than 25 countries and has sales in over 100 countries, emphasizing its extensive global reach [5].
Aurora Spine Announces Initial Surgeries using its AERO™ Lumbar Fusion System
Globenewswire· 2025-07-09 11:15
CARLSBAD, CALIFORNIA, July 09, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in innovative spine and interventional pain management solutions, today announced initial surgeries using Aurora Spine’s newest product, the AERO™ Lumbar Fusion System, have commenced. The minimally invasive procedures using the AERO were conducted by two different surgeons, one ortho surgeon and one interventionalist. The initial surgeries performed were pr ...
InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke
GlobeNewswire News Room· 2025-07-09 11:00
MIAMI, July 09, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Prime carotid stent system for the prevention of stroke, today announced the official commercial launch of the CGuard Prime carotid stent system in the U.S., following its premarket application (PMA) approval from the U.S. Food and Drug Administration (FDA). The CGuard Prime was engineered specifically to minimize both early and late embolism risk by effectively trapping potential emboli against the arterial wal ...
Should You Buy Abbott Stock At $135?
Forbes· 2025-07-09 10:35
Core Viewpoint - Abbott Laboratories has significantly outperformed the S&P 500 index this year, with an 18% increase in stock price compared to the S&P 500's 6% rise, driven by solid quarterly results and positive future forecasts [2] Growth - Abbott Laboratories' revenues have shown slight growth over recent years, with a 4.6% increase from $40 billion to $42 billion in the last 12 months, while the S&P 500 experienced a growth of 5.5% [6] - Quarterly revenues grew by 7.2% to $11 billion in the most recent quarter from $10 billion a year ago, compared to a 4.8% improvement for the S&P 500 [6] Profitability - Abbott Laboratories' operating income over the last four quarters reached $6.8 billion, reflecting a moderate operating margin of 16.3% [5] - The company's net income stood at $13 billion, indicating a high net income margin of 31.9%, compared to 11.6% for the S&P 500 [12] Financial Stability - Abbott Laboratories has a robust balance sheet, with total debt of $15 billion and a market capitalization of $233 billion, resulting in a low debt-to-equity ratio of 6.3% compared to 19.4% for the S&P 500 [12] - The company's operating cash flow was $8.6 billion, yielding a cash flow margin of 20.4%, higher than the S&P 500's 14.9% [12] Downturn Resilience - Abbott Laboratories has demonstrated more resilience than the S&P 500 during recent downturns, with a peak-to-trough decline of 36.2% from a peak of $141.46 on December 27, 2021, compared to a 25.4% decline for the S&P 500 [13] - The stock has shown strong recovery patterns in past crises, fully recovering to pre-crisis peaks in several instances [13] Valuation - Abbott Laboratories' price-to-sales (P/S) ratio is 5.6, compared to 3.1 for the S&P 500, and its price-to-earnings (P/E) ratio is 17.7 against the benchmark's 26.9 [6] - The current valuation appears slightly high compared to the broader market but aligns with the stock's historical average [3][9]
1 No-Brainer Dividend Stock to Buy Now and Hold Forever
The Motley Fool· 2025-07-09 08:31
Publicly traded corporations are under no obligation to pay dividends. Among those that do, many are rather subpar in the exercise, particularly with how often they raise their payouts. That's why companies that increase their dividends every year are highly sought after. These are often industry leaders with robust businesses, strong financial results, and the means to perform well over long periods.Healthcare giant Medtronic (MDT 1.08%) fits that description to a T. Though some might describe the company' ...